Press release
Cystic Fibrosis Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight
Cystic Fibrosis Clinical Trials
Key Takeaways from the Cystic Fibrosis Pipeline Report
• DelveInsight's Cystic Fibrosis pipeline report depicts a robust space with 75+ companies working to develop 80+ pipeline therapies for Cystic Fibrosis treatment.
• The leading companies working in the Cystic Fibrosis Market include Krystal Biotech, Vertex Pharmaceuticals, Translate Bio, Novartis, Algi Pharma, Verona Pharma, Atlantic Healthcare, Calithera Biosciences, Horizon Therapeutics, Santhera Pharmaceuticals, Reveragen Biopharma, Spli Sense, GlaxoSmithKline, EmphyCorp, Abbvie, Galapagos NV, Vertex Pharmaceuticals, PathBio Analytics, AstraZeneca, AxentisPharma AG, and others.
• Promising Cystic Fibrosis Pipeline Therapies in the various stages of development include Ciprofloxacin (Cipro Inhale, BAYQ3939), P-1037, Hypertonic Saline, VX-371 + HS, MP-376 (Levofloxacin solution for Inhalation), and others.
• April 2024:- Krystal Biotech Inc.- KB407-02 A Phase 1 Study of Inhaled KB407, a Replication-Defective, Non-Integrating Vector Expressing Human Cystic Fibrosis Transmembrane Conductance Regulator, for the Treatment of Cystic Fibrosis. This study will evaluate safety and tolerability of ascending doses of nebulized KB407 in adults with cystic fibrosis.
• April 2024:- Vertex Pharmaceuticals Incorporated- The purpose of this study is to evaluate the safety, and tolerability and efficacy of VX-522 in participants 18 years of age and older with cystic fibrosis and a cystic fibrosis transmembrane conductance regulator (CFTR) genotype not responsive to CFTR modulator therapy. A Phase 1/2 Dose Escalation Study Evaluating the Safety, and Tolerability and Efficacy of VX-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and a CFTR Genotype Not Responsive to CFTR Modulator Therapy.
• April 2024:- Boehringer Ingelheim- A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial Evaluating Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BI 1291583 One Tablet Once Daily Over 12 Weeks Versus Placebo in Adult Patients With Cystic Fibrosis Bronchiectasis (Clairafly™)
Request a sample and discover the recent advances in Cystic Fibrosis Treatment Drugs @ Cystic Fibrosis Pipeline Report- https://www.delveinsight.com/sample-request/cystic-fibrosis-pipeline?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
In the Cystic Fibrosis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cystic Fibrosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Cystic Fibrosis Overview
Cystic Fibrosis (CF) is a genetic disorder that primarily affects the lungs, pancreas, and other organs, leading to severe respiratory and digestive challenges. It is caused by mutations in the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) gene, which regulates the movement of salt and water in and out of cells. This dysfunction results in thick, sticky mucus buildup that clogs airways and creates an environment conducive to chronic infections and inflammation.
Respiratory symptoms are a hallmark of Cystic Fibrosis, including persistent coughing, wheezing, and recurrent lung infections. Digestive issues, such as difficulty in absorbing nutrients, malnutrition, and poor growth, stem from blockages in the pancreas that impede enzyme release. Other complications may include diabetes, liver disease, and reduced fertility.
Advances in Cystic Fibrosis care have significantly improved life expectancy, with treatments focusing on airway clearance, infection control, and nutritional support. Breakthrough therapies targeting the defective CFTR protein, such as CFTR modulators, have transformed disease management for eligible patients, offering improved lung function and quality of life.
Despite these advances, challenges remain, particularly for individuals with rare CFTR mutations not addressed by current therapies. Ongoing research continues to focus on innovative treatments and ultimately finding a cure for Cystic Fibrosis.
Find out more about Cystic Fibrosis Therapeutics Assessment @ Cystic Fibrosis Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/cystic-fibrosis-pipeline?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Cystic Fibrosis Emerging Drugs Profile
• OligoG: Algi Pharma
• Ensifentrine: Verona Pharma
• MRT5005: Translate Bio
• CB280: Calithera Biosciences
• KB407 : Krystal Biotech
• SPL84231: SpliSense
Cystic Fibrosis Pipeline Therapeutics Assessment
There are approx. 75+ key companies which are developing the Cystic Fibrosis therapies. The Cystic Fibrosis companies which have their Cystic Fibrosis drug candidates in the most advanced stage, i.e. phase II include, Algi Pharma.
Learn more about the emerging Cystic Fibrosis Pipeline Therapies @ Cystic Fibrosis Clinical Trials Assessment- https://www.delveinsight.com/sample-request/cystic-fibrosis-pipeline?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Cystic Fibrosis Pipeline Report
• Coverage- Global
• Cystic Fibrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Cystic Fibrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Cystic Fibrosis Companies- Krystal Biotech, Vertex Pharmaceuticals, Translate Bio, Novartis, Algi Pharma, Verona Pharma, Atlantic Healthcare, Calithera Biosciences, Horizon Therapeutics, Santhera Pharmaceuticals, Reveragen Biopharma, Spli Sense, GlaxosmithKline, EmphyCorp, Abbvie, Galapagos NV, Vertex Pharmaceuticals, PathBio Analytics, AstraZeneca, AxentisPharma AG, and others.
• Cystic Fibrosis Pipeline Therapies- Ciprofloxacin (Cipro Inhale, BAYQ3939), P-1037, Hypertonic Saline, VX-371 + HS, MP-376 (Levofloxacin solution for Inhalation), and others.
Dive deep into rich insights for new drugs for Cystic Fibrosis Treatment, Visit @ Cystic Fibrosis Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/cystic-fibrosis-pipeline?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content
1. Introduction
2. Executive Summary
3. Cystic Fibrosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Cystic Fibrosis - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company Name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. OligoG : Algi pharma
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. CB280:Calithera Biosciences
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. SPL84231: Spli Sense
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Cystic Fibrosis Key Companies
21. Cystic Fibrosis Key Products
22. Cystic Fibrosis Unmet Needs
23. Cystic Fibrosis Market Drivers and Barriers
24. Cystic Fibrosis Future Perspectives and Conclusion
25. Cystic Fibrosis Analyst Views
26. Cystic Fibrosis Companies
27. Appendix
For further information on the Cystic Fibrosis Pipeline therapeutics, reach out to Cystic Fibrosis Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/cystic-fibrosis-pipeline?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Trending Reports:
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
• Acquired Hemophilia A Pipeline: https://www.delveinsight.com/report-store/acquired-hemophilia-a-pipeline-insight
• Acral Lentiginous Melanoma Market: https://www.delveinsight.com/report-store/acral-lentiginous-melanoma-market
• Acute Intermittent Porphyria Market: https://www.delveinsight.com/report-store/acute-intermittent-porphyria-market
• Acute Pain Market: https://www.delveinsight.com/report-store/acute-pain-market
• Ada-scid Competitive Landscape: https://www.delveinsight.com/report-store/ada-scid-competitive-landscape-and-market-insight
• Adrenal Crisis Market: https://www.delveinsight.com/report-store/adrenal-crisis-market
• Adrenal Insufficiency Market: https://www.delveinsight.com/report-store/adrenal-crisis-market
• Adrenoleukodystrophy Market: https://www.delveinsight.com/report-store/adrenoleukodystrophy-market
• Adult Growth Hormone Deficiency Market: https://www.delveinsight.com/report-store/adult-growth-hormone-deficiency-aghd-market
• Advanced Cancer Pain Management Market: https://www.delveinsight.com/report-store/advanced-cancer-pain-management-market
• Alstrom Syndrome Market: https://www.delveinsight.com/report-store/alstrom-syndrome-market
• Anterior Cruciate Ligament Injuries Market: https://www.delveinsight.com/report-store/anterior-cruciate-ligament-injuries-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Athelete's Foot Market: https://www.delveinsight.com/report-store/athletes-foot-market
• Athlete's Foot Market: https://www.delveinsight.com/report-store/athletes-foot-market
• Bartonellosis Market: https://www.delveinsight.com/report-store/bartonellosis-market
• Bcl-2 Inhibitors Market: https://www.delveinsight.com/report-store/bcl2-inhibitors-market-forecast
• Brain Aneurysm Stents Market: https://www.delveinsight.com/report-store/intracranial-stents-market
• Bronchial Spasm Market: https://www.delveinsight.com/report-store/bronchial-spasm-market
• Bronchial Spasms Market: https://www.delveinsight.com/report-store/bronchial-spasm-market
• Cervical Cancer Market Size: https://www.delveinsight.com/report-store/cervical-cancer-market
• Chemotherapy Induced Febrile Neutropenia Market: https://www.delveinsight.com/report-store/chemotherapy-induced-neutropenia-cin-market
• Chronic Pruritus Market: https://www.delveinsight.com/report-store/chronic-pruritus-market
• Cluster Headache Market: https://www.delveinsight.com/report-store/cluster-headache-market
• Exophthalmos Market: https://www.delveinsight.com/report-store/exophthalmos-market
• Febrile Neutropenia Market: https://www.delveinsight.com/report-store/febrile-neutropenia-market
• France Healthcare Outlook Report: https://www.delveinsight.com/report-store/france-healthcare-outlook-report
• Gastroenteropancreatic Neuroendocrine Tumors Market: https://www.delveinsight.com/blog/gastroenteropancreatic-neuroendocrine-tumours-market
• Giant Papillary Conjunctivitis Market: https://www.delveinsight.com/report-store/giant-papillary-conjunctivitis-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/primary-research-services
Case study: https://www.delveinsight.com/case-study/esmo-conference-coverage
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cystic Fibrosis Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight here
News-ID: 3763171 • Views: …
More Releases from DelveInisight Business Research
Diabetic Foot Ulcers Pipeline 2025: Mechanism of Action, Route of Administration …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Diabetic Foot Ulcers pipeline constitutes 20+ key companies continuously working towards developing 25+ Diabetic Foot Ulcers treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Diabetic Foot Ulcers Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The…
Alpha-1 Antitrypsin Deficiency Pipeline 2025: FDA Updates, Therapy Innovations, …
Alpha-1 Antitrypsin Deficiency pipeline constitutes 12+ key companies continuously working towards developing 12+ Alpha-1 Antitrypsin Deficiency treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Alpha-1 Antitrypsin Deficiency Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Alpha-1 Antitrypsin Deficiency Market.
The Alpha-1 Antitrypsin Deficiency Pipeline report embraces in-depth commercial…
Acute On Chronic Liver Failure Pipeline 2025: Key Companies, MOA, ROA, and Clini …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Acute On Chronic Liver Failure pipeline constitutes 4+ key companies continuously working towards developing 6+ Acute On Chronic Liver Failure treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Acute On Chronic Liver Failure Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental…
Hidradenitis Suppurativa Market Predicted to See Upsurge Through 2034, Highlight …
DelveInsight's "Hidradenitis Suppurativa Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Hidradenitis Suppurativa, historical and forecasted epidemiology as well as the Hidradenitis Suppurativa market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Hidradenitis Suppurativa market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hidradenitis Suppurativa Market Forecast
https://www.delveinsight.com/sample-request/hidradenitis-suppurativa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of…
More Releases for Cystic
Cystic Fibrosis Market Report-Growth with Industry Study, Detailed Analysis | Cy …
The research study contains an in detail descriptive overview and analysis of the Cystic Fibrosis Market, a summary of the market shares constituted by each component, the annual growth of each sector, and the revenue potential of the section. In addition, Cystic Fibrosis Market production and consumption data are used to determine the geographical features.
Get FREE PDF sample of the Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=3639856
Top Company Profile Analysis in this Report-
Cystic Fibrosis…
The Cystic Fibrosis Market to Witness Robust Growth Due to Increasing Cases of C …
Cystic fibrosis is a rare, progressive, life-threatening disease results in the formation of thick mucus that builds up in the lungs, digestive tract, and other parts of the body. If left untreated, it leads to severe digestive and respiratory problems as well as other complications such as infections and diabetes. According to the Cystic Fibrosis Foundation, more than 70,000 people are living with cystic fibrosis around the world. As the…
Cystic Fibrosis Market Opportunity Analysis, 2018-2026
Cystic fibrosis (CF) is a genetic disorder that usually affects the lungs and may also affect the pancreas, kidneys, liver, and intestine. Long-term repercussions including difficulty in breathing and coughing as a result of recurrent lung infections can be seen in CF. Some of the other signs and symptoms include sinus infections, poor growth, infertility in males, fatty stool, and guild of the fingers and toes. Different individuals may have…
Cystic Fibrosis Therapeutics Market Research Reports 2017
This report studies sales (consumption) of Cystic Fibrosis Therapeutics in Europe market, especially in Germany, France, UK, Russia, Italy, Spain and Benelux, focuses on top players in these countries, with sales, price, revenue and market share for each player in these Countries, covering
Vertex Pharmaceuticals , F. Hoffmann-La Roche , AbbVie , Gilead Science , Novartis , AstraZeneca , Bayer , Celtaxsys , Pharmaxis , ProQR Therapeutics , PTC Therapeutics…
Cystic Fibrosis - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Cystic Fibrosis - Heat Map and Analysis to its growing collection of premium market research reports.
Cystic fibrosis (CF) is a progressive genetic condition and is the result of a patient inheriting a faulty cystic fibroses transmembrane conductance regulator (CFTR) gene from both parents. The defective CFTR genes produce faulty CFTR proteins on the body’s epithelial cells, and result in…
Cystic Fibrosis - Heat Map And Analysis
MarketResearchReports.Biz is providing you Latest Market Research report of "Cystic Fibrosis - Heat Map And Analysis".
Cystic fibrosis (CF) is a progressive genetic condition and is the result of a patient inheriting a faulty cystic fibroses transmembrane conductance regulator (CFTR) gene from both parents. The defective CFTR genes produce faulty CFTR proteins on the body?s epithelial cells, and result in the buildup of a thick and sticky mucus in the lungs…
